Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

  • A featured discussion sheds light on how the Combined Risk Score can lead to better breast cancer prevention and screening strategies.

SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new data presentations at the San Antonio Breast Cancer Symposium (SABCS) 2022, including a discussion on prediction of breast cancer risk.

“Genetic testing is an essential tool across the continuum of breast cancer care, allowing physicians to provide advice on a woman’s individual risk and helping them make personalized treatment recommendations upon diagnosis,” said Thomas Slavin, MD, Chief Medical Officer of Myriad Genetics. “The data we present demonstrates our continued commitment to advancing scientific research to improve patient outcomes and to providing products that provide timely, evidence-based medical information to support equitable care for all women.

A myriad of data at SABCS 2022

Spotlight discussion: PD14-05 – Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
Date: Thursday, December 8, 2022, 5:00 p.m. – 6:15 p.m. (CST)
Presenter: Brent Mabey, MSc, Biostatistician II, Myriad Genetics
Performed in collaboration with researchers from several clinics and universities, this study assessed how examining the polygenic risk score (PRS) for women of diverse ancestry, while using ancestry-informative genetic markers combined with version 7 of the Tyrer-Cuzick model, generates a combination risk score that can help predict breast cancer risk.

Poster session: P2-03-23 Retrospective evaluation of outcomes in a real-world prospective cohort using EndoPredict®: Results of the Charité register
Date: Wednesday, December 7, 2022, from 7:00 a.m. to 8:15 a.m. (CST).
Presenters: Teacher. Carsten Denkert, Director of the Institute of Pathology, University Hospital Marburg, Germany.
Performed in collaboration with Charité University Hospital Berlin and University Hospital Marburg, this study conducted an evaluation of patient outcomes in a prospective cohort using EndoPredict.

Additionally, there will also be a poster session (P6-01-24) on an independent study EndoPredict from Klinikum rechts der Isar, Technical University of Munich, Germany, on Friday, December 9 from 7:00 a.m. to 8:15 a.m. CST. The study looked at prospective data on long-term outcomes with EndoPredict for women with early-stage breast cancer.

Poster session: P5-03-03 – Variant classification mismatch: concrete experience of genetic test results in a community setting
Date: Thursday, December 8, 2022, 5:00 p.m. – 6:15 p.m. (CST)
Presenter: Shelly Cummings, MS, CGC, Vice President of Oncology Medical Affairs, Myriad Genetics
This study was conducted in collaboration with Ascension Illinois and provides real-world insight into the results of genetic testing that helps to accurately classify hereditary cancer germline genetic variants for appropriate care.

Among the Myriad products featured in the company’s SABCS exhibit are:

  • MyRisk™ with RiskScore®, Myriad’s market-leading hereditary cancer screening test that offers the first polygenic breast cancer risk assessment for women of all backgrounds. RiskScore provides a personalized 5-year and lifetime risk of developing breast cancer for women eligible for MyRisk.
  • My choice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and state of genomic instability.
  • BRACCDx Analysis® is the only FDA-approved test used to rapidly identify patients with germin BRCA1 and BRCA2 mutations that may be eligible for certain targeted therapies.
  • EndoPredict is a breast cancer prognostic test that helps accurately determine a patient’s 15-year risk of distant recurrence to help physicians identify patients who can safely consider forgoing chemotherapy.
  • Precise™ Oncology Solutions offers a streamlined ordering experience that gives providers the option to receive summarized results for comprehensive germline testing, tumor profiling, and companion diagnostic options, including HRD testing.

Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates using the hashtag #SABCS22.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to promoting health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing a disease or its progression and guide treatment decisions in medical specialties where genetic information can significantly improve patient care and reduce healthcare costs. . fast company named Myriad among the world’s most innovative companies for 2022. For more information, visit

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore , Prolaris, UroSuite, GeneSight and EndoPredict are trademarks or registered trademarks.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s products and its commitment to advancing scientific research to improve patient outcomes. and to provide products that provide timely, data-driven information. medical information to support equitable care for all women. These “forward-looking statements” are based on management’s expectations regarding future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause the results, conditions and actual events differ materially and adversely from those anticipated. These factors include the risks described in the company’s filings with the United States Securities and Exchange Commission, including the company’s annual report on Form 10-K filed on February 25, 2022, as well as any updates of these risk factors filed from time to time in the company’s quarterly reports on Form 10-Q or current reports on Form 8-K.

#Myriad #Genetics #Present #Data #San #Antonio #Breast #Cancer #Symposium #Showcasing #Advances #Breast #Cancer #Risk #Assessment #Treatment

Leave a Comment

Your email address will not be published. Required fields are marked *